Who has been buying Sig Medtech stock?

1 distinct insiders have filed 2 disclosed insider purchases in Sig Medtech (056090), most recently on 2026-01-13. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.

How many insider filings does Sig Medtech have?

Sig Medtech has 2 buy-side and 0 sell-side disclosures on record, covering ₩10M ($7K) in total reported value, spanning 2024-02-07 to 2026-01-13.

Do insider buys in Korean stocks predict returns?

Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Sig Medtech 056090

Company

시지메드텍Sig Medtech

Insiders

Buys

Total Value

₩10M ($7K)

Avg Return

+75.17%

Last Filing

2026-01-13

Sig Medtech (056090) has 2 disclosed insider purchases and 0 disclosed disposals on record, filed by 1 distinct insiders. Together those filings cover ₩10M ($7K) in reported transaction value. The earliest filing StockDrifts holds for Sig Medtech is dated 2024-02-07; the most recent is 2026-01-13. Across these filings the average return since disclosure is +75.17%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

Date	Type	Source	Insider	Position	Shares	Price at filing	Return	Value
2026-09-09	BUY	Market Buy	시지바이오 CG Bio	-	520.0K	₩1,190	+0.0%	₩630M ($438K)
2026-09-08	BUY	Market Buy	시지바이오 CG Bio	-	450.0K	₩1,190	+0.0%	₩531M ($369K)
2026-09-07	BUY	Market Buy	시지바이오 CG Bio	-	400.0K	₩1,190	+0.0%	₩477M ($331K)
2026-09-04	BUY	Market Buy	시지바이오 CG Bio	-	350.0K	-	-	-
2026-09-03	BUY	Market Buy	시지바이오 CG Bio	-	350.0K	-	-	-
2026-01-13	BUY	회사분할	시지바이오 CG Bio	-	9.2M	₩1,401	+109.1%	₩12.9B ($8.9M)
2026-01-13	SELL	회사분할	시지바이오 CG Bio	-	-9.2M	₩1,401	-109.1%	₩12.9B ($8.9M)
2026-01-12	SELL	회사분할	시지바이오 CG Bio	-	-32.6M	₩1,381	-112.2%	₩45.0B ($31.2M)
2026-01-12	BUY	회사분할	시지바이오 CG Bio	-	32.6M	₩1,381	+112.2%	₩45.0B ($31.2M)
2024-10-31	BUY	제3자배정유상증자	시지바이오 CG Bio	-	9.2M	₩1,331	+120.1%	₩12.2B ($8.5M)
2024-06-14	BUY	Market Buy	정주미 Joomi Jeong	CEO	3.0K	₩1,527	+91.9%	₩5M ($3K)
2024-06-11	BUY	Market Buy	정주미 Joomi Jeong	CEO	3.0K	₩1,849	+58.5%	₩6M ($4K)
2024-02-16	BUY	장외매수	시지바이오 CG Bio	-	4.6M	₩2,360	+24.1%	₩10.8B ($7.5M)
2024-02-14	BUY	유상신주취득	시지바이오 CG Bio	-	14.0M	₩2,360	+24.1%	₩33.0B ($22.9M)
2024-02-07	BUY	장외매수	시지바이오 CG Bio	-	14.0M	₩2,360	+24.1%	₩33.0B ($22.9M)

Frequently asked questions

Who has been buying Sig Medtech stock?: 1 distinct insiders have filed 2 disclosed insider purchases in Sig Medtech (056090), most recently on 2026-01-13. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Sig Medtech have?: Sig Medtech has 2 buy-side and 0 sell-side disclosures on record, covering ₩10M ($7K) in total reported value, spanning 2024-02-07 to 2026-01-13.
Do insider buys in Korean stocks predict returns?: Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

More on this data

Every trade listed above comes from an official regulatory disclosure. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.